Get started

Biotech

$ABT Cup and Handle Pattern Formation on DailySentiment: Bullish Reasons: Technical Analysis & News Catalyst News has just been released that $ABT has been approved by the U.S to begin working on a 5$ rapid COVID-19 antigen test. I find this to be huge considering the inconvenience in searching for a COVID testing facility in certain places in the U.S as well as the discomfort associated with the actual process. In addition price action is just nice if Im being honest. It has underwent a long series of consolidation and converging trendlines and is due for a breakout.
NYSE:ABTLong
by DannyNoburu
Hold your breath peopleIf you have viewed my posts about IBIO , you would have witness the long term yellow line cutting through the 1.6-1.8 price point. Either this drop is to retest the long term channel or ... well... good luck to those that still believe in the company. I like the innovative company and the CEO's track record and was invested since $0.3. I really appreciate the person that referred me to IBIO on yahoo chatroom in Feb. I have started to trimmed my position when this started to breaking through all the support level like a hot knife through butter below the $3 dollar range. Wish the bulls good luck! just need one proper PR and this beast will rocket. stay safe! Side thought: I have seen in many chatroom and witness many high PT for all different kind of ticker (i guess you reading this have as well). Especially, 'this company has XXX product and it deserve XXX price' ,' this company will save the world '. I mean i am sure that biotech companies have all the smartest people in the world and they deserve tremendous net worth for all they have done for humanity, but unfortunately, this is a money society.Invest safe and wise people. Companies pulling moves like Novavax and Overstock are rare; i believe it is more luck than any other reason.
I
by jordanadriano
4
breaking out in a few days? PT 17-18In my previous idea, i stated that IBIO would consolidate around mid 4 area until next breakout but it was not how it ended. With Russian news and insider dumping, IBIO went back all the way to its breakout point. Currently, it is touching the trend drawn all the way from the beginning of the year that connects two breakout point (green line, breakout points are drawn in blue). Is it ready for a run? If it runs, i expect PT of 17-18 then retracement. retracement levels shown on figure (10 dollar, worst case scenario $6-7)
ILong
by jordanadriano
6
NSPR still dippingOkay I'm gonna start off with the news News -NSPR beat earnings by 44%, yet still losing money. It has been making more money due to its past performance and not losing as much. We can project that they might be profitable next year. -Their offering that was held in June came out that it was so they can remain compliant with the exchange. That Friday they have became fully compliant so they won't get delisted. -On their earnings report they got mostly compliant FDA IDE approval, yet on that they will get fully compliant FDA IDE approval in 45days. This should be on the 27th, so next week, which I labeled on the graph. -Upcoming catalist: they hope to get into the France and China markets soon. Plus with approval in Brazil we could see that profit from the company in q4/ another earnings beat. Maybe over 100%, yet with COVID not sure, but certain in q1 next year. TA -Not sure what to say since an earnings beat should have pushed the price higher, yet we saw a sell off with no FDA IDE approval to common investors liking. At the same time the volume showed it being very low compared to the past showing its just small sellers and yesterday someone bought 200k shares touching our old trading zone. -the low at .4194 was in the middle of the gap of the intial drop from .80 to .39 then gaping up to .42-.47 Final thoughts I'm DCAing this stock and think its gonna pay off pretty soon. Recent SEC filing shows that their CFO has sign a contract starting in 2022 that he will get an annual renewal of his job. This shows there is some long term potential if a CFO is entering this contract and wants to see growth in this company or he will get fired. There was alot more in the earnings report like and they don't want to do any more offerings and they also have alot of cash on hand to play with, so upside potential is pretty high.
NLong
by nathanielx9
ArcticZymes turnaround & firing on all cylindersThe Turnaround of ArcticZymes is now definitive. For the second quarter we see impressive growth and the company is firing on all cylinders. Opex (cost) going down while earnings as well as profits surge. ArcticZymes Q2 report Sales of NOK 44.3 million (16.9) +262% EBITDA of NOK 27.2 million (-0.5) Cash-flow for the Q2 was NOK 20.4 million (-6.8) Cash at hand NOK 56,1 million Gross margin 90% CEO Jethro Holter says in the earnings call: "The main growth driver has been sales of the Salt Active Nuclease (SAN) products to the therapeutics segment. The SAN products continue to attract new customers who are developing gene therapies and vaccines. Furthermore, our well-established customers are regularly submitting substantially larger orders as they advance their development programs." Full report pdf here: newsweb.oslobors.no text: newsweb.oslobors.no
OSL:AZTLong
by kulturdesken
2
GNBT: Penny stock, speculative biotech to considerUp sharply today on news (see below) Looks to me like forming a likely inverse head and shoulders pattern. Often with H&S there is a fairly symmetrical time difference between and shoulders and the top or bottom as we have here (horizontal arrows). Like all biotechnology stocks this could be a bust or very volatile. "Generex Signs a Memorandum of Understanding with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia."
GLong
by goodguy
2
Merck a strong value with strong technicals and upcoming newsI've been holding Merck since its big dip to $76 back in June. At the time I set a price target of $82: However, I didn't sell at $82 and have continued to hold the stock due to strong fundamentals, technicals, news, and sentiment. Merck has positive earnings and sales growth, with PEG ratio of 1.7 and PSG ratio of 2.3. It has a nice dividend yield at 2.9%, a rarity for a stock with such strong growth. Analysts rate it highly, with an average score of 80.25/100 from S&P Global and an Equity Starmine Summary Score of 8.5/10. With a put/call ratio of 0.41, sentiment on Merck is stronger than on most of the other stocks I watch. It's got a good ESG score and a long history of beating analyst estimates. Plus it's poised to benefit from some hype around its antiviral drug intended to fight Covid-19 that starts clinical trials in September. In technical terms, Merck recently broke out of a triangle, got a couple bullish moving average crosses, and today broke out above its recent trading range. If Merck oscillates down to its moving averages, I may use that as an opportunity to add to my position. I think the stock still has plenty of upside, especially when the clinical trial headlines start to hit.
NYSE:MRKLong
by ChristopherCarrollSmith